Dr. Ligon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
75 Francis Street
Boston, MA 02115Phone+1 617-732-5500
Summary
- Dr. Keith Ligon is Pathologist and Chief of Neuropathology at the MGB-Brigham and Women's Hospital and Dana-Farber Cancer Institute in Boston, MA. He is affiliated with multiple hospitals in the area, including Mass General Brigham's Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Boston Children's Hospital. He received his medical degree from MD Anderson Cancer Center and McGovern Medical School at UTHealth and has been in practice 20 years. He specializes in neuropathology, anatomic pathology, pediatric pathology, and molecular diagnostics. He is experienced in oncologic pathology. He has more than 200 publications and over 500 citings.
Education & Training
Brigham and Women's HospitalResidency, Pathology-Anatomic and Clinical, 1997 - 2001
McGovern Medical School at UTHealthClass of 1997- Brigham and Women's HospitalFellowship, Neuropathology
Certifications & Licensure
MA State Medical License 2001 - 2025- American Board of Pathology Anatomic Pathology
- American Board of Pathology Neuropathology
Clinical Trials
- Imatinib Mesylate in Treating Patients With Recurrent Meningioma Start of enrollment: 2003 Feb 01
- Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma Start of enrollment: 2005 Apr 01
- Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors Start of enrollment: 2007 May 25
- Join now to see all
Publications & Presentations
PubMed
- 303 citationsLongitudinal molecular trajectories of diffuse glioma in adultsFloris P. Barthel, Kevin C. Johnson, Frederick S. Varn, Anzhela D. Moskalik, Georgette Tanner
Nature. 2019-12-05 - 50 citationsIndividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Gliobl...Brian M. Alexander, Lorenzo Trippa, Sarah C. Gaffey, Isabel Arrillaga-Romany, Eudocia Q. Lee
JCO Precision Oncology. 2019-03-27 - 207 citationsInhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysisNathan Mathewson, Orr Ashenberg, Itay Tirosh, Simon Gritsch, Elizabeth M. Perez
Cell. 2021-03-04
Journal Articles
- Immunophenotyping of Pediatric Brain Tumors: Correlating Immune Infiltrate with Histology, Mutational Load, and Survival and Assessing Clonal T Cell ResponseIsaac H Solomon, Mark W Kieran, Gabriel K Griffin, Pratiti Bandopadhayay, Jerome Ritz, Ashley S Plant, Keith L Ligon, Glenn Dranoff, Journal of Neuro-Oncology
Press Mentions
Weighing Cancer Cells Helps Predict Treatment OutcomesOctober 14th, 2021- Cancer Drug Response and Outcome Predicted from Cell Mass ChangesOctober 7th, 2021
- New Study Finds Link Between Patient Survival and Changes in Tumor Cell Mass in Brain CancerOctober 6th, 2021
- Join now to see all
Grant Support
- Shared Resources CoreNational Cancer Institute2011–2012
- OLIG Function In CNS Development And TumorigenesisNational Institute Of Neurological Disorders And Stroke2006–2008
- OLIG Function In CNS Development And TumorigenesisNational Institute Of Neurological Disorders And Stroke2004–2005
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
